Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jan;84(2):263–269. doi: 10.1054/bjoc.2000.1579

Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer

F Tanaka 1, Y Otake 1, K Yanagihara 1, T Yamada 1, R Miyahara 1, Y Kawano 1, M Li 1, K Inui 1, H Wada 1
PMCID: PMC2363717  PMID: 11161386

Abstract

To examine whether efficacy of postoperative oral administration of UFT, a 5-fluorouracil derivative chemotherapeutic agent, may be influenced by incidence of apoptosis (apoptosis index) or apoptosis-related gene status (p53 and bcl-2) of the tumour, a total of 162 patients with pathologic stage I non-small cell lung cancer were retrospectively reviewed. UFT was administrated postoperatively to 44 patients (UFT group), and not to the other 118 patients (Control group). For all patients, 5-year survival rate of the UFT group (79.9%) seemed higher than that of the Control group (69.8%), although without significant difference (P = 0.054). For patients with higher apoptotic index, 5-year survival rate of the UFT group (83.3%) was significantly higher than that of the Control group (67.6%, P = 0.039); for patients with lower apoptotic index, however, there was no difference in the prognosis between these two groups. Similarly, UFT was effective for patients without p53 aberrant expression (5-year survival rates: 95.2% for the UFT group and 74.3% for the Control group, P = 0.022), whereas not effective for patients with p53 aberrant expression. Bcl-2 status did not influence the efficacy of UFT. In conclusion, apoptotic index and p53 status are useful factors to predict the efficacy of postoperative adjuvant therapy using UFT. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: p53, bcl-2, apoptosis, adjuvant therapy, 5-fluorouracil, UFT

Full Text

The Full Text of this article is available as a PDF (158.8 KB).

Footnotes

Parts of this article was presented at the 34th annual meeting of ASCO (Los Angeles, CA, abstract No. 2110) and the 35th annual meeting of ASCO (Atlanta, GA, abstract No. 2393).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergh J., Norberg T., Sjögren S., Lindgren A., Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995 Oct;1(10):1029–1034. doi: 10.1038/nm1095-1029. [DOI] [PubMed] [Google Scholar]
  2. Carbone D. P., Mitsudomi T., Chiba I., Piantadosi S., Rusch V., Nowak J. A., McIntire D., Slamon D., Gazdar A., Minna J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest. 1994 Dec;106(6 Suppl):377S–381S. [PubMed] [Google Scholar]
  3. Clarke A. R., Purdie C. A., Harrison D. J., Morris R. G., Bird C. C., Hooper M. L., Wyllie A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993 Apr 29;362(6423):849–852. doi: 10.1038/362849a0. [DOI] [PubMed] [Google Scholar]
  4. Fujii S., Ikenaka K., Fukushima M., Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gan. 1978 Dec;69(6):763–772. [PubMed] [Google Scholar]
  5. Fujiwara T., Grimm E. A., Mukhopadhyay T., Zhang W. W., Owen-Schaub L. B., Roth J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994 May 1;54(9):2287–2291. [PubMed] [Google Scholar]
  6. Gasparini G., Barbareschi M., Doglioni C., Palma P. D., Mauri F. A., Boracchi P., Bevilacqua P., Caffo O., Morelli L., Verderio P. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res. 1995 Feb;1(2):189–198. [PubMed] [Google Scholar]
  7. Holmgren L., O'Reilly M. S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995 Feb;1(2):149–153. doi: 10.1038/nm0295-149. [DOI] [PubMed] [Google Scholar]
  8. Ikenaka K., Shirasaka T., Kitano S., Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gan. 1979 Jun;70(3):353–359. [PubMed] [Google Scholar]
  9. Kerr J. F., Wyllie A. H., Currie A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972 Aug;26(4):239–257. doi: 10.1038/bjc.1972.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  11. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  12. Lowe S. W., Bodis S., McClatchey A., Remington L., Ruley H. E., Fisher D. E., Housman D. E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 1994 Nov 4;266(5186):807–810. doi: 10.1126/science.7973635. [DOI] [PubMed] [Google Scholar]
  13. Lowe S. W., Schmitt E. M., Smith S. W., Osborne B. A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993 Apr 29;362(6423):847–849. doi: 10.1038/362847a0. [DOI] [PubMed] [Google Scholar]
  14. Mountain C. F. Revisions in the International System for Staging Lung Cancer. Chest. 1997 Jun;111(6):1710–1717. doi: 10.1378/chest.111.6.1710. [DOI] [PubMed] [Google Scholar]
  15. Pastorino U., Andreola S., Tagliabue E., Pezzella F., Incarbone M., Sozzi G., Buyse M., Menard S., Pierotti M., Rilke F. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997 Aug;15(8):2858–2865. doi: 10.1200/JCO.1997.15.8.2858. [DOI] [PubMed] [Google Scholar]
  16. Pazdur R., Lassere Y., Rhodes V., Ajani J. A., Sugarman S. M., Patt Y. Z., Jones D. V., Jr, Markowitz A. B., Abbruzzese J. L., Bready B. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 1994 Nov;12(11):2296–2300. doi: 10.1200/JCO.1994.12.11.2296. [DOI] [PubMed] [Google Scholar]
  17. Pezzella F., Turley H., Kuzu I., Tungekar M. F., Dunnill M. S., Pierce C. B., Harris A., Gatter K. C., Mason D. Y. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993 Sep 2;329(10):690–694. doi: 10.1056/NEJM199309023291003. [DOI] [PubMed] [Google Scholar]
  18. Pinedo H. M., Peters G. F. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988 Oct;6(10):1653–1664. doi: 10.1200/JCO.1988.6.10.1653. [DOI] [PubMed] [Google Scholar]
  19. Sen S., D'Incalci M. Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett. 1992 Jul 27;307(1):122–127. doi: 10.1016/0014-5793(92)80914-3. [DOI] [PubMed] [Google Scholar]
  20. Symonds H., Krall L., Remington L., Saenz-Robles M., Lowe S., Jacks T., Van Dyke T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994 Aug 26;78(4):703–711. doi: 10.1016/0092-8674(94)90534-7. [DOI] [PubMed] [Google Scholar]
  21. Tanaka F., Kawano Y., Li M., Takata T., Miyahara R., Yanagihara K., Ohtake Y., Fukuse T., Wada H. Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2728–2736. doi: 10.1200/JCO.1999.17.9.2728. [DOI] [PubMed] [Google Scholar]
  22. Tanaka F., Miyahara R., Ohtake Y., Yanagihara K., Fukuse T., Hitomi S., Wada H. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg. 1998 Sep;14(3):256–264. doi: 10.1016/s1010-7940(98)00186-9. [DOI] [PubMed] [Google Scholar]
  23. Tanaka F., Miyahara R., Ohtake Y., Yanagihara K., Fukuse T., Hitomi S., Wada H. Lewis Y antigen expression and postoperative survival in non-small cell lung cancer. Ann Thorac Surg. 1998 Nov;66(5):1745–1750. doi: 10.1016/s0003-4975(98)00937-0. [DOI] [PubMed] [Google Scholar]
  24. Tanaka F., Yanagihara K., Ohtake Y., Miyahara R., Kawano Y., Fukuse T., Hitomi S., Wada H. p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer. Jpn J Cancer Res. 1999 Apr;90(4):432–438. doi: 10.1111/j.1349-7006.1999.tb00766.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wada H., Hitomi S., Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol. 1996 Apr;14(4):1048–1054. doi: 10.1200/JCO.1996.14.4.1048. [DOI] [PubMed] [Google Scholar]
  26. Wada H., Miyahara R., Tanaka F., Hitomi S. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg. 1999 Apr;15(4):438–443. doi: 10.1016/s1010-7940(99)00031-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES